Evidence map›Paper›PMID 33493615›Full record

Trial reportInternational journal of radiation oncology, biology, physics2021

Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients.

Ritchell van Dams, Naomi Y Jiang, Donald B Fuller, Andrew Loblaw, Tommy Jiang, Alan J Katz, Sean P Collins, Nima Aghdam, Simeng Suy, Kevin L Stephans and 8 more

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of radiation oncology, biology, physics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 59 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Management of high-risk prostate cancer in Spain: results from a national patterns of care survey.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  5. Prognostic significance of the mEPE score in intermediate-risk prostate cancer patients undergoing ultrahypofractionated robotic SBRT.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 3 countries.

Ritchell van DamsDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
Naomi Y JiangDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
Donald B FullerGenesis Healthcare Partners, San Diego, California.
Andrew LoblawDepartment of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
Tommy JiangUniversity of California, Los Angeles, Los Angeles, California.
Alan J KatzFROS Radiation Oncology and CyberKnife Center, Flushing, New York.
Sean P CollinsDepartment of Radiation Medicine, Georgetown University Hospital, Washington, DC.
Nima AghdamDepartment of Radiation Medicine, Georgetown University Hospital, Washington, DC.
Simeng SuyDepartment of Radiation Medicine, Georgetown University Hospital, Washington, DC.
Kevin L StephansDepartment of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Ye YuanDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
Nicholas G NickolsDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
Vedang MurthyDepartment of Radiation Oncology, Tata Memorial Hospital, Mumbai, India.
Tejshri P TelkhadeTata Memorial Hospital, Mumbai, India.
Patrick A KupelianDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
Michael L SteinbergDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
Tahmineh RomeroUniversity of California, Los Angeles, Los Angeles, California.
Amar U KishanDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, California. Electronic address: AUKishan@mednet.ucla.edu.
University of California, Los Angeles · USGeorgetown University · USTata Memorial Hospital · INCleveland Clinic · USGenesis Healthcare · USPancreatic Cancer Action Network · USUniversity of Toronto · CA

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
NCATS NIH HHS UL1 TR001881
6 · The paper itself

Abstract

purposeTo explore the efficacy and toxicity of stereotactic body radiation therapy (SBRT) in high-risk prostate cancer (HRPCa) in a consortium of 7 institutional phase 2 trials and prospective registries. METHODS AND MATERIALS: Individual patient data were pooled for 344 patients with a minimum follow-up of 24 months. Biochemical recurrence-free survival (BCRFS) and distant metastasis-free survival (DMFS) were estimated using a Kaplan-Meier framework. Fine and Gray competing risk and Cox proportional hazards regression models were developed to assess the association between time to BCR and time to distant metastasis and prespecified variables of interest. Logistic regression models were developed to evaluate associations between acute and late grade ≥2 genitourinary and gastrointestinal and the following a priori-specified variables: age, dose per fraction, ADT use, and nodal radiation therapy.

resultsMedian follow-up was 49.5 months. Seventy-two percent of patients received ADT, with a median duration of 9 months, and 19% received elective nodal radiation therapy. Estimated 4-year BCRFS and DMFS rates were 81.7% (95% CI, 77.2%-86.5%) and 89.1% (95% CI, 85.3%-93.1%). The crude incidences of late grade ≥3 genitourinary and gastrointestinal toxicity were 2.3% and 0.9%.

conclusionsThese data support a favorable toxicity and efficacy profile for SBRT for HRPCa. Further prospective studies are needed to evaluate the optimal dose and target volume in the context of SBRT for HRPCa.

Indexed as

Prostatic NeoplasmsRadiosurgeryAgedAged, 80 and overAndrogen AntagonistsClinical Trials, Phase II as TopicDisease-Free SurvivalFollow-Up StudiesGastrointestinal TractHumansLymphatic IrradiationMaleMiddle AgedProportional Hazards ModelsProspective StudiesProstate-Specific AntigenAndrogen AntagonistsProstate-Specific Antigen

Identifiers

PMID33493615
PMCPMC8956505
OpenAlexW3122772564

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.